Anti-TREK-1 Autoantibodies in SCVF: A Multicenter Look
Official title: Circulating Anti-TREK-1 Autoantibodies as Diagnostic and Prognostic Biomarkers in Short-Coupled Ventricular Fibrillation
Run by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · NCT06943365 · Data updated 2026-11-12
Researchers are testing whether anti-TREK-1 autoantibodies are linked to short-coupled ventricular fibrillation and if they can help diagnose or predict outcomes in adults with SCVF.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval Academic / other |
| Locations | 5 sites (Vancouver, British Columbia and 4 other locations) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | July 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT06943365 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a diagnosis of SCVF who are willing to provide informed consent.
✕Probably not a fit
SCVF patients without anti-TREK-1 antibodies or without a clear link to arrhythmia risk may not see a diagnostic or prognostic benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This translational, multicenter observational study investigates whether circulating anti-TREK-1 autoantibodies serve as biomarkers for SCVF. It includes repeat plasma screenings and genetic haplotype analysis, alongside functional studies in patient-derived cardiac cells and single-cell transcriptomics to understand TREK-1’s role in arrhythmogenesis. The study design combines observational biomarker work with laboratory experiments to connect antibody presence with cellular mechanisms. Participants are adults diagnosed with SCVF, enrolled across multiple Canadian centers, with data collection focused on diagnostic and prognostic implications. No interventional treatment is being tested; the emphasis is on biomarker validation and mechanistic insight.
Why it matters
Potential benefit: If successful, the findings could lead to a blood test that helps diagnose SCVF and predict risk, guiding management and monitoring.
How similar studies have gone: Preliminary data suggest a link between TREK-1 antibodies and SCVF, but the translational, multicenter validation is still needed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of SCVF as per current criteria * Willingness to provide written informed consent Exclusion Criteria: \- SCVF patients \< age 18
Where it's running
-
Institut universitaire de cardiologie et pneumologie de Québec
Québec, Quebec, Canada Recruiting -
St-Paul's Hospital - University of British Columbia
Vancouver, British Columbia, Canada Not yet recruiting -
Phri
Hamilton, Ontario, Canada Active not recruiting -
Ottawa Heart Center
Ottawa, Ontario, Canada Not yet recruiting -
Amsterdam University Medical Center
Amsterdam, Netherlands Active not recruiting
Study contacts
- Principal investigator: Christian Steinberg, MD — Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Study coordinator: Marina Sanchez, PhD
- Email: marina.sanchez@criucpq.ulaval.ca
- Phone: +14186568711
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose beta-blocker treatment for adults who survived unexplained ventricular fibrillation
This trial will try low-dose beta-blockers in adults who survived an out-of-hospital cardiac arrest with no clear cause to see if it reduces dangerous heart rhythms and ICD therapies.
-
Systematic 14-day ambulatory heart monitoring after TAVI
After TAVI, patients with certain heart conduction abnormalities will try 14 days of wearable ECG monitoring to see if it lowers the chances of sudden death, symptomatic heart rhythm problems, or stroke within a year compared to standard follow-up.
-
General anesthesia versus conscious sedation for radial endobronchial ultrasound
This trial will see if general anesthesia or conscious sedation gives better diagnostic results for adults undergoing radial endobronchial ultrasound to sample peripheral lung nodules.
-
Evaluating the SAPIEN 3 Ultra RESILIA Valve for Aortic Stenosis
This study tests how well the new SAPIEN 3 Ultra RESILIA valve works for people with severe aortic stenosis who are getting a heart valve replacement, by checking its performance over the next 10 years.
-
Transcatheter closure versus medical therapy for PFO in older adults
This tests whether closing a patent foramen ovale (PFO) with a catheter plus usual medicines prevents another unexplained (cryptogenic) stroke in people over 60 better than medicines alone.
-
Optimizing heart valve function using echocardiography or catheterization after valve replacement
This study is testing whether using ultrasound or a catheter to check heart valve function after a replacement helps patients with aortic valve problems feel better and have better outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.